The real-world safety profile of pemetrexed and platinum with or without pembrolizumab: insights from a comparative analysis of FAERS database
Abstract Background Lung cancer (LC) is a leading cause of cancer-related mortality worldwide. The combination of immune checkpoint inhibitors (ICIs) with chemotherapy significantly extends survival but increases the risk of treatment-related toxicity. To explore the impact of adding pembrolizumab t...
Saved in:
| Main Authors: | Shun Li, Zhifei Huang, Xiaoyu Zhong, Yan Zhou, Hao Jiang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14171-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pembrolizumab plus Pemetrexed and Platinum in Metastatic Non-Squamous Non-Small Cell Lung Cancer: A Real-Life Study at a Portuguese Centre
by: Maria João Santos, et al.
Published: (2025-02-01) -
Acute pancreatitis caused by pemetrexed, carboplatin, and gemcitabine in a patient with lung cancer: A rare case report
by: Vishal Kulkarni, et al.
Published: (2019-01-01) -
A rare presentation of the diffuse dermal mucinosis in adenocarcinoma of the lungs treated with pembrolizumab and pemetrexed
by: Karen Koch, MBChB (UCT), FCDerm (SA), FRACP, MMed (Derm), et al.
Published: (2025-07-01) -
Use of combined chemotherapy and immunotherapy improves pulmonary arterial hypertension
by: Tejaswini P. Reddy, et al.
Published: (2024-07-01) -
Real-world study on adverse drug reactions of pembrolizumab in endometrial cancer treatment: insights from the FAERS database
by: Huiping Zhang, et al.
Published: (2025-08-01)